-3.12%
16.54%
46.23%
0.00%
-12.92%
-70.92%
-92.03%
AI Spotlight on ATAI
Company Description
Atai Life Sciences N.V., through its subsidiary, ATAI Life Sciences AG, operates as a clinical-stage biopharmaceutical company.It engages in developing various therapeutic candidates that focuses on various mental health disorders.The company's therapeutic candidates include PCN-101, a subcutaneous formulation of R-ketamine for the treatment of treatment-resistant depression (TRD); RL-007, a cholinergic, glutamatergic, and GABA-B receptor modulator to treat cognitive impairment associated with schizophrenia; DMX-1002, an oral formulation of ibogaine for treating opioid use disorder (OUD); GRX-917, an oral formulation of a deuterated version of etifoxine for the generalized anxiety disorder treatment; and NN-101, a novel intranasal formulation of N-acetylcysteine to treat mild traumatic brain injuries.
Its therapeutic candidates also comprise VLS-01, a formulation of N,N-dimethyltryptamine for treating TRD; EMP-01, an oral formulation of an 3,4-methyl enedioxy methamphetamine for the treatment of post-traumatic stress disorder; RLS-01, a formulation of Salvinorin A for TRD; KUR-101, an oral formulation of deuterated mitragynine to treat OUD; and DMX-1001, an oral formulation of noribogaine for the treatment of OUD.The company was formerly known as Adripa Holding B.V. Atai Life Sciences N.V. was founded in 2018 and is headquartered in Berlin, Germany.
Market Data
| Last Price | 1.55 |
| Change Percentage | -3.12% |
| Open | 1.61 |
| Previous Close | 1.6 |
| Market Cap ( Millions) | 260 |
| Volume | 1093813 |
| Year High | 2.85 |
| Year Low | 1.03 |
| M A 50 | 1.5 |
| M A 200 | 1.45 |
Financial Ratios
| FCF Yield | -30.47% |
| Dividend Yield | 0.00% |
| ROE | -66.03% |
| Debt / Equity | 16.34% |
| Net Debt / EBIDTA | 5.06% |
| Price To Book | 1.71 |
| Price Earnings Ratio | -1.94 |
| Price To FCF | -3.28 |
| Price To sales | 785.78 |
| EV / EBITDA | -2.09 |
News
- Jan -29 - Atai Life Sciences: Positive BPL-003 Data In AUD Leads To Another Catalyst
- Jan -28 - atai Life Sciences poised for near-term value creation with release of psychedelics trial data: analysts
- Jan -28 - atai Life Sciences unveils positive results from Beckley Psytech's alcohol use disorder trial
- Jan -27 - Spravato sales surged highlights commercial viability of psychedelics, analysts believe
- Jan -10 - atai Life Sciences announces leadership appointments to advance psychedelic therapeutics pipeline
- Jan -10 - atai Life Sciences Announces Key Leadership Appointments as it Advances its Pipeline of Novel Psychedelic Therapeutics for Mental Health
- Nov -14 - atai Life Sciences shares set to be lifted by 2025 trial data readouts: analysts
- Nov -13 - atai Life Sciences advances therapeutic pipeline in Q3 with FDA approval of VLS-01
- Nov -12 - RFK Jr's appointment in health could accelerate psychedelic drug development, analysts say
- Oct -02 - IntelGenx is Granted Court Approval of the Sale Proposal from atai Life Sciences AG
- Sep -04 - atai Life Sciences to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
- Sep -03 - Psychedelic Stock Deep Dive: Atai Life Sciences
- Aug -17 - atai Life Sciences chief scientific officer details VLS-01 trial success - ICYMI
- Aug -14 - atai Life Sciences entering catalyst-rich period with key Phase2/3 trial data ahead
- Aug -13 - atai Life Sciences advances clinical pipeline in Q2, unveils positive VLS-01 trial results
- Aug -13 - atai Life Sciences Reports Second Quarter 2024 Financial Results and Provides Corporate Updates
- Aug -12 - Psychedelic drug contender stocks drop after FDA rejects MDMA treatment
- Aug -07 - atai Life Sciences to Participate in the Canaccord Genuity 44th Annual Growth Conference
- Jul -11 - atai Life Sciences (ATAI) Upgraded to Buy: Here's What You Should Know
- Jul -11 - 3 Dirt-Cheap Drug Developers With Blockbuster Potential
Business Breakdown
Expected Mid-Term Growth
Segment n°1 -> Mental Health Innovations
Expected Growth : 15.1 %
What the company do ?
Mental Health Innovations from Atai Life Sciences N.V. develops novel therapeutics for mental health disorders, focusing on psychedelic compounds and digital therapeutics.
Why we expect these perspectives ?
Growing demand for mental health treatments, increasing awareness of psychedelic compounds' potential, and advancements in digital therapeutics drive growth in Atai Life Sciences' novel therapeutics for mental health disorders.
Atai Life Sciences N.V. Products
| Product Range | What is it ? |
|---|---|
| Ketamine | A medication primarily used as an anesthetic agent for surgery and other painful procedures |
| MDMA | A psychoactive drug known for its empathogenic and stimulant effects |
| Psilocybin | A naturally occurring psychedelic compound found in certain species of mushrooms |
| DMT | A powerful psychedelic compound found in various plants and animals |
| Ibogaine | A naturally occurring psychoactive compound found in the roots of the Tabernanthe iboga plant |
| Ayahuasca | A plant-based psychedelic brew traditionally used in shamanic rituals |
Atai Life Sciences N.V.'s Porter Forces
Threat Of Substitutes
Atai Life Sciences N.V. operates in a highly competitive industry, and there are several substitutes available for its products. However, the company's strong brand recognition and customer loyalty mitigate the threat of substitutes to some extent.
Bargaining Power Of Customers
Atai Life Sciences N.V. has a diverse customer base, which reduces the bargaining power of individual customers. Additionally, the company's products are often critical to its customers' operations, making it difficult for customers to negotiate prices.
Bargaining Power Of Suppliers
Atai Life Sciences N.V. relies on a few key suppliers for certain raw materials, which gives these suppliers some bargaining power. However, the company's strong relationships with its suppliers and its ability to negotiate contracts mitigate this risk to some extent.
Threat Of New Entrants
The biotechnology industry is highly competitive, and new entrants can easily disrupt the market with innovative products and services. Atai Life Sciences N.V. needs to continuously innovate and invest in research and development to stay ahead of new entrants.
Intensity Of Rivalry
The biotechnology industry is highly competitive, and Atai Life Sciences N.V. faces intense rivalry from established players and new entrants. The company needs to focus on differentiating its products and services to maintain its market share.
Strength
Weaknesses
Opportunities
Threats
Capital Structure
| Value | |
|---|---|
| Debt Weight | 5.99% |
| Debt Cost | 8.56% |
| Equity Weight | 94.01% |
| Equity Cost | 8.56% |
| WACC | 8.56% |
| Leverage | 6.37% |
Atai Life Sciences N.V. : Quality Control
Atai Life Sciences N.V. passed 5 out of 9 key points:
Historical Valuation
Price/Earnings Ratio
Margin Valuation
Peers Valuation
Competitors
| Company | Rational |
|---|---|
| PHM.MC | Pharma Mar, S.A., a biopharmaceutical company, engages in the research, development, production, and commercialization of bio-active principles of marine origin for use in oncology in Spain, Italy, Germany, Ireland, rest … |
| GUBRA.CO | Gubra A/S operates as a biotech company with two primary areas of business: pre-clinical contract research (CRO) services and proprietary early target and drug discovery programs. The CRO segment offers … |
| HYL.BR | Hyloris Pharmaceuticals SA engages in the develop, manufacture, and deliver pharmaceutical products to address unmet medical needs in cardiovascular health, oncology, women's health, and other major therapeutic areas. The company … |
| BIOA-B.ST | BioArctic AB (publ), a research-intensive biopharmaceutical company, develops biological drugs for patients with neurodegenerative disorders in Sweden. The company develops BAN2401, an immunotherapy, which is in Phase III clinical trials … |
| BSLN.SW | Basilea Pharmaceutica AG, a commercial stage biopharmaceutical company, focuses on the development of products that address the medical needs in the therapeutic areas of oncology and anti-infectives. It offers Cresemba, … |
Peers Metrics
DCF BETA
Expected Cash-Flows
Scoring Insights
Peers Group Analysis
🥇
Pharma Mar
A-Score
1-Year Total Return ->
🥈
Gubra
A-Score
1-Year Total Return ->
🥉
Basilea Pharmaceutica
A-Score
1-Year Total Return ->
4
BioArctic
A-Score
1-Year Total Return ->
5
Atai Life Sciences
A-Score
1-Year Total Return ->
6
